Overview

Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study assess the pharmacokinetics of vildagliptin in mild, moderate and severe renal impaired patients
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Vildagliptin